Jeanene Swanson

Blog Post

FDA Accepts Sarepta Therapeutics’ New Drug Application (NDA) for Golodirsen to Treat DMD Amenable to Exon 53 Skipping

By Jeanene Swanson | March 1, 2019
Blog Post

Long-Term Results of Extension Study Validate Surgery as a Treatment for Myasthenia Gravis

By Jeanene Swanson | February 12, 2019
Blog Post

Solid Biosciences Announces Preliminary Results of DMD Gene Therapy Trial

By Jeanene Swanson | February 8, 2019
MDA logo
Blog Post

Catalyst Pharmaceuticals Announces Positive Results from Phase 2b Trial of Firdapse in Patients with Muscle-Specific Kinase Antibody Positive Myasthenia Gravis (MuSK-MG)

By Jeanene Swanson | January 30, 2019
MDA logo
Blog Post

FDA Awards Fast Track Status to RNS60, Revalesio’s Investigational Therapy for ALS

By Jeanene Swanson | January 16, 2019
Blog Post

MDA Awards Venture Philanthropy Grant to AcuraStem to Develop Treatment for ALS

By Jeanene Swanson | January 15, 2019
Blog Post

Wave Life Sciences Announces Phase 2/3 Duchenne Muscular Dystrophy Clinical Trial of Suvodirsen (WVE-210201) Selected for FDA Complex Innovative Trial Designs Pilot Program

By Jeanene Swanson | January 8, 2019
Blog Post

FDA Grants Orphan Drug Designation to Myonexus Therapeutics’ MYO-102 Gene Therapy Drug for Limb-Girdle Muscular Dystrophy Type 2D

By Jeanene Swanson | January 4, 2019